Clinical Trials
64 trialsAlvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Sumitomo Pharma America, Inc.
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
AML
Sumitomo Pharma Co., Ltd.
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
M.D. Anderson Cancer Center
Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
Canadian Cancer Trials Group
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Canadian Cancer Trials Group
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
National Institutes of Health Clinical Center (CC)
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
National Cancer Institute (NCI)
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
National Cancer Institute (NCI)
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
National Cancer Institute (NCI)
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Alvocidib in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
National Cancer Institute (NCI)
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
National Cancer Institute (NCI)
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
National Cancer Institute (NCI)
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Refractory or Recurrent Solid Tumors
Memorial Sloan Kettering Cancer Center
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)